Hrvatska -
hrvatski -
HALMED (Agencija za lijekove i medicinske proizvode)
dimenium 50 mikrograma + 100 mikrograma u jednoj dozi, prašak inhalata, dozirani
elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 100 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 100 mikrograma flutikazonpropionata
Hrvatska -
hrvatski -
HALMED (Agencija za lijekove i medicinske proizvode)
dimenium 50 mikrograma + 250 mikrograma u jednoj dozi, prašak inhalata, dozirani
elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 250 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 250 mikrograma flutikazonpropionata
Hrvatska -
hrvatski -
HALMED (Agencija za lijekove i medicinske proizvode)
dimenium 50 mikrograma + 500 mikrograma u jednoj dozi, prašak inhalata, dozirani
elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 500 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 500 mikrograma flutikazonpropionata
Hrvatska -
hrvatski -
HALMED (Agencija za lijekove i medicinske proizvode)
3m neutralne elektrode
medical intertrade d.o.o., sveta nedelja - neutralne elektrode koje pružaju siguran put elektrokirurške struje
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
Bosna i Hercegovina -
hrvatski -
Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)
sevorane 100 %/1 boca para za inhalaciju, tečnost
abbvie d.o.o. - севофлюран - para za inhalaciju, tečnost - 100 %/1 boca - 1 boca sa parom za inhalaciju, tečnosti sadrži: 100% sevofluran
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
opzelura
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostali dermatološki pripravci - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.